Kemwell has completed the groundbreaking ceremony for a new biopharmaceutical manufacturing plant in Bangalore, India, in collaboration with Boehringer Ingelheim, Germany.
The new 15,000m2 state-of-the-art facility will handle process development, fermentation, purification and formulation of biologics for early-phase preclinical and clinical studies.
It will comprise cGMP drug substance manufacturing and a sterile fill and finish facility for drug product with a floor for laboratories to support production of protein therapeutics from mammalian-cell culture or microbial fermentation.
Kemwell will initially have access to Boehringer Ingelheim's cell line development using BI's HEX technology, followed by preferred access to the large-scale commercial production of BI's facilities in Europe.
"Kemwell and Boehringer Ingelheim will provide the customer with state-of-the-art technology from Europe along with the benefit of low cost manufacturing from India," said Anurag Bagaria, vice president of Kemwell.
The Kemwell factory will share synergies with the other facilities on the Bangalore site that manufacture tablets, semi-solids and liquids as well as offering pharmaceutical development services.
"Kemwell will continue to build on its extensive experience in contract manufacturing. We find many opportunities for supplying monoclonal antibodies and are committed to provide these services in a timely and cost-effective manner," Bagaria added.
"Through the partnership with Kemwell Biologics, Boehringer Ingelheim will strengthen its presence for biologic services in Asia, providing state-of-the-art technologies for economic manufacturing of innovative, high quality biopharmaceuticals," said Professor Rolf Werner, corporate senior vice president of Boehringer Ingelheim's biopharmaceuticals division.